Close Menu

NEW YORK (Genomeweb) – ArcherDx announced on Monday an agreement to develop and commercialize a next generation sequencing-based companion diagnostic for Celgene's investigational drug CC-122 for diffuse large B cell lymphoma.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.